trending Market Intelligence /marketintelligence/en/news-insights/trending/_yykmy7qbn2_eqrkut3mcq2 content esgSubNav
In This List

Syros Pharmaceuticals names director; 2 board members step down

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Syros Pharmaceuticals names director; 2 board members step down

Syros Pharmaceuticals Inc. appointed Michael Bonney to its board of directors.

Bonney is CEO and board chair of biotechnology company Kaleido Biosciences and is also chairman of the boards of Alnylam Pharmaceuticals Inc. and Magenta Therapeutics Inc.

His previous roles include CEO of Cubist Pharmaceuticals LLC, now owned by Merck & Co. Inc., and vice president of sales and marketing at Biogen Inc.

In addition, Syros directors Robert Nelson and Sanj Patel stepped down from the board.

Cambridge, Mass.-based Syros Pharmaceuticals is a biopharmaceutical company focused on cancer and monogenic diseases.